These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. Peter FW; Benkovic C; Muehlberger T; Vogt PM; Homann HH; Kuhnen C; Wiebalck A; Steinau HU Br J Haematol; 2002 Jun; 117(3):658-63. PubMed ID: 12028039 [TBL] [Abstract][Full Text] [Related]
44. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403. Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871 [TBL] [Abstract][Full Text] [Related]
45. New peptide pENW (pGlu-Asn-Trp) inhibits platelet activation by attenuating Akt phosphorylation. Xiong J; Bai L; Fang W; Fu J; Fang W; Cen J; Kong Y; Li Y Eur J Pharm Sci; 2012 Apr; 45(5):552-8. PubMed ID: 22285483 [TBL] [Abstract][Full Text] [Related]
46. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
47. Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. van Giezen JJ; Jansen JW Thromb Haemost; 1992 Jul; 68(1):69-73. PubMed ID: 1514175 [TBL] [Abstract][Full Text] [Related]
48. A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations. Millet J; Theveniaux J; Pascal M Thromb Res; 1987 Jan; 45(2):123-33. PubMed ID: 3563978 [TBL] [Abstract][Full Text] [Related]
49. [Antithrombotic activity of RU-891 antiaggregant agent]. Spasov AA; Kucheriavenko AF; Tian' M; Anisimova VA Eksp Klin Farmakol; 2013; 76(6):25-6. PubMed ID: 24003486 [TBL] [Abstract][Full Text] [Related]
50. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. Rebello SS; Miller BV; Basler GC; Lucchesi BR J Cardiovasc Pharmacol; 1997 Feb; 29(2):240-9. PubMed ID: 9057074 [TBL] [Abstract][Full Text] [Related]
51. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972 [TBL] [Abstract][Full Text] [Related]
52. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595 [TBL] [Abstract][Full Text] [Related]
53. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation. Münzer P; Borst O; Walker B; Schmid E; Feijge MA; Cosemans JM; Chatterjee M; Schmidt EM; Schmidt S; Towhid ST; Leibrock C; Elvers M; Schaller M; Seizer P; Ferlinz K; May AE; Gulbins E; Heemskerk JW; Gawaz M; Lang F Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):61-71. PubMed ID: 24233488 [TBL] [Abstract][Full Text] [Related]
54. Platelets Express Activated P2Y Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879 [TBL] [Abstract][Full Text] [Related]
55. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785 [TBL] [Abstract][Full Text] [Related]
56. Rapid effects of aldosterone on platelets, coagulation, and fibrinolysis lead to experimental thrombosis augmentation. Gromotowicz-Poplawska A; Marcinczyk N; Misztal T; Golaszewska A; Aleksiejczuk M; Rusak T; Chabielska E Vascul Pharmacol; 2019; 122-123():106598. PubMed ID: 31655164 [TBL] [Abstract][Full Text] [Related]
57. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet. Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377 [TBL] [Abstract][Full Text] [Related]
58. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866 [TBL] [Abstract][Full Text] [Related]
59. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Hosokawa K; Ohnishi T; Fukasawa M; Kondo T; Sameshima H; Koide T; Tanaka KA; Maruyama I Microvasc Res; 2012 Mar; 83(2):154-61. PubMed ID: 22166857 [TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors. Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]